JP2020523327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523327A5 JP2020523327A5 JP2019568003A JP2019568003A JP2020523327A5 JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5 JP 2019568003 A JP2019568003 A JP 2019568003A JP 2019568003 A JP2019568003 A JP 2019568003A JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- group
- heart failure
- compound selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517211P | 2017-06-09 | 2017-06-09 | |
| US62/517,211 | 2017-06-09 | ||
| PCT/US2018/036631 WO2018227065A1 (en) | 2017-06-09 | 2018-06-08 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523327A JP2020523327A (ja) | 2020-08-06 |
| JP2020523327A5 true JP2020523327A5 (enExample) | 2021-07-26 |
| JP7183193B2 JP7183193B2 (ja) | 2022-12-05 |
Family
ID=62779078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568003A Expired - Fee Related JP7183193B2 (ja) | 2017-06-09 | 2018-06-08 | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11186544B2 (enExample) |
| EP (1) | EP3634412A1 (enExample) |
| JP (1) | JP7183193B2 (enExample) |
| KR (1) | KR102623473B1 (enExample) |
| CN (1) | CN110996950B (enExample) |
| WO (1) | WO2018227065A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717708B2 (en) * | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7094989B2 (ja) | 2017-06-09 | 2022-07-04 | ブリストル－マイヤーズ スクイブ カンパニー | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2019173182A1 (en) | 2018-03-05 | 2019-09-12 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| JP7494224B2 (ja) * | 2019-06-18 | 2024-06-03 | ブリストル－マイヤーズ スクイブ カンパニー | ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト |
| EP3789378A1 (en) * | 2019-09-06 | 2021-03-10 | Grünenthal GmbH | Piperidines or piperidones substituted with urea and heteroaryl |
| EP4178946A1 (en) | 2020-07-09 | 2023-05-17 | Bristol-Myers Squibb Company | Oxopyrrolidine fpr2 agonists |
| ES2986512T3 (es) | 2020-07-09 | 2024-11-11 | Bristol Myers Squibb Co | Agonistas del receptor 2 del péptido formil pirazolona |
| WO2022035923A1 (en) | 2020-08-12 | 2022-02-17 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002303264A1 (en) * | 2001-04-09 | 2002-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic inhibitors of factor xa |
| US7678913B2 (en) * | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| SG11201406629VA (en) * | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| EP3305763B1 (en) | 2013-11-28 | 2019-07-24 | Kyorin Pharmaceutical Co., Ltd. | Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists |
| WO2016189877A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| AU2016266190A1 (en) * | 2015-05-27 | 2018-01-18 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| KR20180081528A (ko) | 2015-11-24 | 2018-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 |
| US10717708B2 (en) * | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7155102B2 (ja) * | 2016-07-07 | 2022-10-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素 |
| TW201815762A (zh) | 2016-09-21 | 2018-05-01 | 德商歌林達有限公司 | 經尿素及苯基取代之６員環狀胺或內醯胺 |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7094989B2 (ja) * | 2017-06-09 | 2022-07-04 | ブリストル－マイヤーズ スクイブ カンパニー | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| WO2019173182A1 (en) * | 2018-03-05 | 2019-09-12 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| JP7494224B2 (ja) * | 2019-06-18 | 2024-06-03 | ブリストル－マイヤーズ スクイブ カンパニー | ビアリールジアルキルホスフィンオキシドｆｐｒ２アゴニスト |
-
2018
- 2018-06-08 WO PCT/US2018/036631 patent/WO2018227065A1/en not_active Ceased
- 2018-06-08 CN CN201880050610.9A patent/CN110996950B/zh not_active Expired - Fee Related
- 2018-06-08 EP EP18735093.9A patent/EP3634412A1/en not_active Withdrawn
- 2018-06-08 KR KR1020207000292A patent/KR102623473B1/ko active Active
- 2018-06-08 JP JP2019568003A patent/JP7183193B2/ja not_active Expired - Fee Related
- 2018-06-08 US US16/619,956 patent/US11186544B2/en active Active